MedTrace Logo

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

NCT03395080 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2025-08-01

Study results available
· View outcomes & findings →

Summary

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma

Conditions

Interventions

DRUG

Paclitaxel

Administered by IV infusion

DRUG

300mg DKN-01

Administered by IV infusion

DRUG

600mg DKN-01

Administered by IV infusion

Sponsors & Collaborators

  • Leap Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Cynthia Sirard · Leap Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-05
Primary Completion
2020-09-09
Completion
2021-01-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03395080 on ClinicalTrials.gov